These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 9332313

  • 1. Immune function in patients with beta thalassaemia receiving the orally active iron-chelating agent deferiprone.
    Loebstein R, Dalal I, Nisbet-Brown E, Berkovitch M, Meydan N, Andrews D, Loubser MD, Koren G, Roifman CM, Olivieri NF.
    Br J Haematol; 1997 Sep; 98(3):597-600. PubMed ID: 9332313
    [Abstract] [Full Text] [Related]

  • 2. Alternate use of deferiprone and desferrioxamine in primary school children with thalassaemia major.
    Aydinok Y, Nisli G, Kavakli K.
    Br J Haematol; 1999 Jul; 106(1):252-3. PubMed ID: 10444196
    [No Abstract] [Full Text] [Related]

  • 3. Adherence to desferrioxamine and deferiprone and the impact of deferiprone co-prescription in thalassaemia major patients. Does the addition of deferiprone improve adherence?
    Kidson-Gerber G, Lindeman R.
    Br J Haematol; 2008 Aug; 142(4):679-80. PubMed ID: 18537970
    [No Abstract] [Full Text] [Related]

  • 4. Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility.
    Kontoghiorghes GJ, Kolnagou A.
    Lancet; 2003 Jan 11; 361(9352):184. PubMed ID: 12531621
    [No Abstract] [Full Text] [Related]

  • 5. Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility.
    Brittenham GM, Nathan DG, Olivieri NF, Pippard MJ, Weatherall DJ.
    Lancet; 2003 Jan 11; 361(9352):183; author reply 183-4. PubMed ID: 12531619
    [No Abstract] [Full Text] [Related]

  • 6. Monitoring long-term efficacy of iron chelation therapy by deferiprone and desferrioxamine in patients with beta-thalassaemia major: application of SQUID biomagnetic liver susceptometry.
    Fischer R, Longo F, Nielsen P, Engelhardt R, Hider RC, Piga A.
    Br J Haematol; 2003 Jun 11; 121(6):938-48. PubMed ID: 12786807
    [Abstract] [Full Text] [Related]

  • 7. Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility.
    St Pierre TG.
    Lancet; 2003 Jan 11; 361(9352):182; author reply 183-4. PubMed ID: 12531617
    [No Abstract] [Full Text] [Related]

  • 8. Immune and neural status of thalassemic patients receiving deferiprone or combined deferiprone and deferoxamine chelation treatment.
    Tourkantoni N, Athanassiou-Metaxa M, Zafiriou D, Tzimouli V, Economou M, Taparkou A, Perifanis V, Kanakoudi-Tsakalidou F.
    Hemoglobin; 2008 Jan 11; 32(1-2):35-40. PubMed ID: 18274981
    [Abstract] [Full Text] [Related]

  • 9. Prevention of Iron Overload and Long Term Maintenance of Normal Iron Stores in Thalassaemia Major Patients using Deferiprone or Deferiprone Deferoxamine Combination.
    Kolnagou A, Kontoghiorghe CN, Kontoghiorghes GJ.
    Drug Res (Stuttg); 2017 Jul 11; 67(7):404-411. PubMed ID: 28320041
    [Abstract] [Full Text] [Related]

  • 10. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major.
    Olivieri NF, Brittenham GM, McLaren CE, Templeton DM, Cameron RG, McClelland RA, Burt AD, Fleming KA.
    N Engl J Med; 1998 Aug 13; 339(7):417-23. PubMed ID: 9700174
    [Abstract] [Full Text] [Related]

  • 11. Antihistone and other autoantibodies in beta-thalassemia major patients receiving iron chelators.
    Pradhan V, Badakere S, Ghosh K.
    Acta Haematol; 2003 Aug 13; 109(1):35-9. PubMed ID: 12486321
    [Abstract] [Full Text] [Related]

  • 12. Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility.
    Fischer R, Engelhardt R.
    Lancet; 2003 Jan 11; 361(9352):182-3; author reply 183-4. PubMed ID: 12531618
    [No Abstract] [Full Text] [Related]

  • 13. Chromosomal aberration frequencies in patients with thalassaemia major undergoing therapy with deferiprone and deferoxamine in a comparative crossover study.
    Marshall R, Tricta F, Galanello R, Leoni G, Kirkland D, Minto S, Spino M.
    Mutagenesis; 2003 Sep 11; 18(5):457-63. PubMed ID: 12960415
    [Abstract] [Full Text] [Related]

  • 14. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major.
    Borgna-Pignatti C, Cappellini MD, De Stefano P, Del Vecchio GC, Forni GL, Gamberini MR, Ghilardi R, Piga A, Romeo MA, Zhao H, Cnaan A.
    Blood; 2006 May 01; 107(9):3733-7. PubMed ID: 16373663
    [Abstract] [Full Text] [Related]

  • 15. Deferiprone: a review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases.
    Barman Balfour JA, Foster RH.
    Drugs; 1999 Sep 01; 58(3):553-78. PubMed ID: 10493280
    [Abstract] [Full Text] [Related]

  • 16. Immune status of thalassemic patients receiving deferiprone or combined deferiprone and desferrioxamine chelation treatment.
    Athanassiou-Metaxa M, Tzimouli V, Economou M, Taparkou A, Tourkantoni N, Kanakoudi-Tsakalidou F.
    Acta Haematol; 2003 Sep 01; 110(4):224-6. PubMed ID: 14663175
    [No Abstract] [Full Text] [Related]

  • 17. Sequential alternating deferiprone and deferoxamine treatment compared to deferiprone monotherapy: main findings and clinical follow-up of a large multicenter randomized clinical trial in -thalassemia major patients.
    Pantalone GR, Maggio A, Vitrano A, Capra M, Cuccia L, Gagliardotto F, Filosa A, Romeo MA, Magnano C, Caruso V, Argento C, Gerardi C, Campisi S, Violi P, Malizia R, Cianciulli P, Rizzo M, D'Ascola DG, Quota A, Prossomariti L, Fidone C, Rigano P, Pepe A, D'Amico G, Morabito A, Gluud C.
    Hemoglobin; 2011 Sep 01; 35(3):206-16. PubMed ID: 21599433
    [Abstract] [Full Text] [Related]

  • 18. Oral deferiprone for iron chelation in people with thalassaemia.
    Roberts DJ, Brunskill SJ, Doree C, Williams S, Howard J, Hyde CJ.
    Cochrane Database Syst Rev; 2007 Jul 18; (3):CD004839. PubMed ID: 17636775
    [Abstract] [Full Text] [Related]

  • 19. Sequential use of deferiprone and desferrioxamine in primary school children with thalassaemia major in Turkey.
    Aydinok Y, Nisli G, Kavakli K, Coker C, Kantar M, Cetingül N.
    Acta Haematol; 1999 Jul 18; 102(1):17-21. PubMed ID: 10473883
    [Abstract] [Full Text] [Related]

  • 20. Effects of combined deferiprone with deferoxamine on right ventricular function in thalassaemia major.
    Alpendurada F, Smith GC, Carpenter JP, Nair SV, Tanner MA, Banya W, Dessi C, Galanello R, Walker JM, Pennell DJ.
    J Cardiovasc Magn Reson; 2012 Jan 25; 14(1):8. PubMed ID: 22277065
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.